ClinicalTrials.gg
CompletedNCT00409942TORAFICUpdated Jul 15, 2009

Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

A Phase 4 interventional study of Torasemide Prolonged Release and Furosemide in Congestive Heart Failure, sponsored by Ferrer Internacional S.A.. Completed at 23 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-15.

Sponsored by Ferrer Internacional S.A. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
142
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 341 studies in Heart Failure with a site in Spain — 76 open to participants now, 98 under way, 21 of them phase 3. Heart Failure · Spain.

Enrollment
179th of 263
142 · median 294
Started
2007
with 6 others
Phase 4
24 of 341
2 open now
Registered
13th of 341
by date

Among the 341 studies in Heart Failure with a site in Spain, this one is the 179th largest by enrollment of the 263 interventional ones that give a count, is one of 7 that started in 2007, is one of 24 in phase 4, and was the 13th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 341 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

71 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been developed a new formulation of Torasemide (Torasemide prolonged release).

The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart failure (Class II-IV of the New York Heart Association Classification.

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

Keywords

  • Chronic heart failure
  • Torasemide prolonged release
  • Myocardial fibrosis
  • Loop diuretics
  • Peptide of procollagen type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 18
  • Patients with chronic heart failure class II-IV ()due to arterial hypertension
  • Patients clinically stable who required diuretic treatment
  • Patients with left ventricular hypertrophy diagnosed by echocardiogram
  • Patients without ischaemic cardiopathy or non recent disease
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Heart Failure due to aortic stenosis or hypertrophic myocardiopathy
  • Recent coronary syndrome (less than 3 months)
  • Recent myocardial infarction (less than 6 months)
  • Unstable angor pectoris
  • Severe cardiac arrhythmia
  • Pregnancy or breastfeeding
  • Aldosterone antagonists (last 6 months)
  • Current loop diuretic treatment over study doses (torasemide > 10mg/day furosemide > 40 mg/day)
  • known to study drugs
  • Liver disease ( or AST > twice upper normal limt)
  • Renal impairment (Serum creatinine > 2,5mg/dl)
  • Insulin-dependent diabetes
  • Patient included in another simultaneous study
  • Lactose intolerance
  • Lithium Concomitant treatment
  • Chronic treatment with NSAIDs
  • Concomitant treatment with aminoglycoside antibiotics,etacrynic acid
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    1

    Torasemide prolonged released

    Drug: Torasemide Prolonged Release

  • Active comparator
    2

    Furosemide

    Drug: Furosemide

Interventions

  • DrugTorasemide Prolonged Release

    Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months

    Also known as: Torasemide Prolonged release:Sutril neo

  • Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months

    Also known as: Furosemide: Seguril

06

What researchers measure

Primary outcomes

  1. Myocardial fibrosis reduction:measure of Serum carboxy-terminal peptide of procollagen type 1.

    Time frame: 8 months

Secondary outcomes

  1. Clinical improvement (New York Heart Association classification, signs and symptoms of heart failure)

    Time frame: 8 months

  2. Cardiovascular events

    Time frame: 8 months

  3. NT-proBNP (Brain Natriuretic Peptide)

    Time frame: 8 months

  4. Hospitalizations, home care due to cardiovascular causes related to heart failure

    Time frame: 8 months

  5. Safety and tolerability

    Time frame: 8 months

  6. Quality of Life (Minnesota Test)

    Time frame: 8 months

07

Study locations

23 sites
  • Central Hospital
    Oviedo, Asturias, Spain
  • Canet de Mar, Primary Care Centre
    Canet de Mar, Barcelona, Spain
  • Centelles - Primar Care Centre
    Centellas, Barcelona, Spain
  • El Maresme - Primary Care Centre
    Mataró, Barcelona, Spain
  • Remei, Primary care centre
    Vic, Barcelona, Spain
  • Begonte - Primary Care Centre
    Begonte, Lugo, Spain
  • Clinico Universitario Virgen de la Victoria
    Málaga, Malaga, Spain
  • Donostia Hospital
    Donostia, San Sebastián, Spain
  • Alcover - primary care centre
    Alcover, Tarragona, Spain
  • Clinc Hospital
    Barcelona, Spain
  • Germans Trias i Pujol Hospital
    Barcelona, Spain
  • H. del Mar
    Barcelona, Spain
  • Valle Hebrón Hospital
    Barcelona, Spain
  • Reina Sofia Hospital
    Córdoba, Spain
  • Josep Trueta Hospital
    Girona, Spain
  • San Jorge Hospital
    Huesca, Spain
  • Complejo Hospitalario Juan Canalejo
    La Coruña, Spain
  • Gregorio Marañón Hospital
    Madrid, Spain
  • Virgen de la Arrixaca
    Murcia, Spain
  • Clinico Universitario Hospital
    Salamanca, Spain
  • Clinico Universitario de Santiago
    Santiago de Compostela, Spain
  • General Hospital
    Valencia, Spain
  • Clinico Universitario
    Zaragoza, Spain
08

References and documents

Publications

  • Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004 Sep 7;110(10):1263-8. doi: 10.1161/01.CIR.0000140973.60992.9A. Epub 2004 Aug 16. PubMed 15313958 ↗
  • Gonzalez A, Lopez B, Diez J. New directions in the assessment and treatment of hypertensive heart disease. Curr Opin Nephrol Hypertens. 2005 Sep;14(5):428-34. doi: 10.1097/01.mnh.0000174143.30045.bd. PubMed 16046900 ↗
  • Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004 Jun 2;43(11):2028-35. doi: 10.1016/j.jacc.2003.12.052. PubMed 15172408 ↗
  • Lopez B, Gonzalez A, Querejeta R, Diez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens. 2005 Aug;23(8):1445-51. doi: 10.1097/01.hjh.0000173780.67308.f1. PubMed 16003166 ↗
  • Lopez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007 Aug 28;50(9):859-67. doi: 10.1016/j.jacc.2007.04.080. Epub 2007 Aug 13. PubMed 17719472 ↗
  • TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther. 2011 Sep;33(9):1204-1213.e3. doi: 10.1016/j.clinthera.2011.08.006. Epub 2011 Sep 8. PubMed 21906812 ↗
  • Diez J, Coca A, de Teresa E, Anguita M, Castro-Beiras A, Conthe P, Cobo E, Fernandez E; TORAFIC Investigators Group. TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. Expert Rev Cardiovasc Ther. 2009 Aug;7(8):897-904. doi: 10.1586/erc.09.74. PubMed 19673667 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2006
First posted
Dec 12, 2006
Start
Mar 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Last update
Jul 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00409942
First posted
Dec 12, 2006
Start date
Mar 2007
Primary completion
Jun 2009
Completion
Jun 2009
Last update
Jul 15, 2009

Study contacts

Antonio Coca, MD, PhD
study chair · Hospital Clinic of Barcelona
Manuel Anguita, MD, PhD
study chair · Hospital Reina Sofia - Córdoba
Eduardo De Teresa, MD, PhD
study chair · Hospital Clinico - Málaga
Alfonso Castro Beiras, MD, PhD
study chair · Hospital Juan Canalejo - Coruña
Javier Díez
study director · Centro Investigación Médica Aplicada (CIMA) - Pamplona (Navarra)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion